Previous PostPalvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita
Next PostTiE Boston recognizes Purnanand Sarma, Ph.D. President & CEO of Immunome, as 2020 Lifetime Achievement Awardee